Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332

Harvard University, Cambridge, Massachusetts, United States
The Journal of Infectious Diseases (Impact Factor: 5.78). 01/2005; 190(12):2167-74. DOI: 10.1086/425903
Source: PubMed

ABSTRACT This study evaluates the safety, tolerance, and pharmacokinetics of stavudine (d4T) in human immunodeficiency virus (HIV)-infected zidovudine (ZDV)-intolerant/refusing pregnant women and of single-dose d4T in their infants. Women received d4T and lamivudine (3TC) from enrollment until labor. During labor, women received oral 3TC and either intravenous or oral d4T. Infants received ZDV and 3TC for 6 weeks and a single dose of oral d4T at weeks 1 and 6. Mean maternal antenatal d4T pharmacokinetics (terminal plasma half-life [T1/2], 83.5+/-16.8 min; area under the plasma-concentration time curve [AUC0-infinity), 81.6+/-22.0 microg.min/mL; n=6) were not significantly different from those during labor (T(1/2), 87.3+/-24.7 min; AUC0-infinity, 88.1+/-16.6 microg.min/mL; n=6). Umbilical-cord and maternal plasma concentrations were not significantly different from one another. The oral clearance of d4T in infants was significantly greater at week 6 versus week 1 (6.8+/-1.0 vs. 5.6+/-1.2 mL/min/kg). There were no toxicities, in women or infants, that required discontinuation or modification of the study drug. No infants had positive HIV viral diagnostic tests. d4T with or without 3TC is a potential alternative to ZDV for HIV-infected pregnant women.

Download full-text


Available from: Lynne M Mofenson, Sep 17, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Combination antiretroviral regimens including nelfinavir (NFV) are commonly used in pregnancy. We studied the safety, antiviral effect, and pharmacokinetics of NFV and its M8 metabolite with two dosing regimens in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-infected pregnant women. HIV-infected pregnant women between 14 and 34 weeks gestation received NFV (Cohort 1: 750 mg tid, n = 10; Cohort 2: 1250 mg bid, n = 23) with ZDV and 3TC. Serial blood sampling for NFV concentrations was performed antepartum (AP) and 6 weeks postpartum (PP). Maternal and cord blood samples were also obtained at delivery. NFV and M8 levels were determined by high-performance liquid chromatography. The pharmacokinetic (PK) target was an extrapolated NFV AUC0-24 > 30 mug . h/mL. Mothers were followed frequently for potential clinical and laboratory toxicity. Overall, NFV in combination with ZDV and 3TC was well tolerated. The PK target was met in 3/8 AP and 5/7 PP in Cohort 1 and 17/21 AP and 16/17 PP in Cohort 2. When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP. The average M8/NFV ratio was increased PP compared to AP (0.085 vs. 0.29, p < .001). Placental transfer of NFV was low with a median cord blood:maternal plasma ratio at delivery of 0.05. Maternal mean CD4+ T cell counts increased significantly and plasma HIV-1 RNA levels decreased from entry to delivery and 6 to 12 weeks postpartum. NFV used in combination with ZDV and 3TC was well tolerated in pregnant HIV-infected women and produced a significant improvement in HIV disease parameters. NFV drug exposure is inadequate in most pregnant women receiving 750 mg tid but is much improved with 1250 mg bid. NFV crosses the placenta poorly. The AP increase in NFV oral clearance and decrease in M8/NFV ratio suggest that CYP3A activity increases relative to CYP2C19 activity during pregnancy.
    HIV Clinical Trials 03/2008; 9(2):115-25. DOI:10.1310/hct0902-115 · 2.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV-infected pregnant women should be offered antiretroviral (ARV) prophylaxis to prevent perinatal HIV transmission, as well as optimal therapies for their own health. Since the risk of vertical transmission decreases with lower maternal viral load, combination therapies exhibit a more pronounced antiviral efficacy than monotherapy in preventing such transmission. The investigation of placental transfer remains one of the cornerstones of pregnancy risk assessment. In vivo and ex vivo studies have established that maternal-fetal transfer of nucleoside analogs occurs rapidly suggesting a simple diffusion mechanism. The clearance index of HIV protease inhibitors (PI) at therapeutic levels is extremely low, with no accumulation in placental tissue. The low HIV PI placental transfer has been confirmed by in vivo studies and can be explained by their high plasma protein binding and liposolubility (except for indinavir whose placental transfer is high). In contrast with these findings, the nevirapine (non-nucleoside reverse transcriptase inhibitor) maternal/cord blood ratio averaged unity, indicating a high placental transfer. Finally some studies, physical-chemistry and pharmacokinetics properties regarding new drugs, show no enfuvirtide placental transfer, intermediate transfer of maraviroc and raltegravir and a high transfer of tenofovir and emtricitabine.
    Antibiotiques 12/2010; 12(4):228-234. DOI:10.1016/j.antib.2010.09.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antiretrovirals may be used in pregnant women infected with the HIV and their newborns both for treatment of maternal HIV disease and for prevention of mother-to-child transmission of HIV. More than 25 antiretroviral agents in 5 classes have been approved, with new drugs and classes in development. This article reviews current knowledge of the pharmacology of these drugs during pregnancy and in the newborn period, highlighting those pharmacologic issues critical to the safe and effective use of antiretrovirals in these populations.
    Clinics in perinatology 12/2010; 37(4):907-27, xi. DOI:10.1016/j.clp.2010.08.006 · 2.13 Impact Factor